Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry
2018; Volume: 11; Issue: 1 Linguagem: Inglês
10.4168/aair.2019.11.1.43
ISSN2092-7363
AutoresMin‐Hye Kim, Sang‐Heon Kim, So‐Young Park, Ga‐Young Ban, Joo‐Hee Kim, Jae‐Woo Jung, Ji‐Yong Moon, Woo‐Jung Song, Hyouk‐Soo Kwon, Jae‐Woo Kwon, Jae‐Hyun Lee, Hye–Ryun Kang, Jong‐Sook Park, Tae‐Bum Kim, Heung‐Woo Park, Kwang Ha Yoo, Yeon‐Mok Oh, Young‐Il Koh, An‐Soo Jang, Byung‐Jae Lee, Young-Joo Cho, Sang‐Heon Cho, Hae‐Sim Park, Choon‐Sik Park, Ho Joo Yoon, You Sook Cho,
Tópico(s)Allergic Rhinitis and Sensitization
ResumoPurpose: Although mild to moderate asthma is much more common, the morbidity and mortality of severe asthma are much higher.This study was performed to identify and analyze the clinical characteristics of severe asthma in Korea.Methods: We registered patients with severe refractory asthma into the Severe Asthma Registry supported by the Severe Asthma Work Group of the Korean Academy of Asthma, Allergy and Clinical Immunology.Patients were enrolled since 2010 from the 15 university hospitals nationwide in Korea.Severe asthma was defined according to modified European Respiratory Society/American Thoracic Society criteria.Information on demographics, medical history, pulmonary function tests and skin prick tests was collected; the clinical characteristics of severe asthmatics were analyzed from the collected data.Results: A total of 489 patients were enrolled with a mean age of 62.3; 45% are male.Sixty percent of patients received Global Initiative for Asthma step 4 treatment, and 30% received step 5 treatment.The most common comorbidities were allergic rhinitis (58.7%).Aspirin hypersensitivity was observed in 14.0%.Approximately half (53.9%) are non-smokers.Atopy was proven in 38.5% of the patients.Regarding asthma medications, inhaled corticosteroids and long-acting β-agonist combination inhalers were most commonly prescribed (96.5%), followed by leukotriene antagonists (71.0%).A recombinant anti-immunoglobulin E monoclonal antibody (omalizumab) has been used in 1.8% of the patients.The mean forced
Referência(s)